{"count":839,"next":"http://glycodata.org/api/gdd/glyco-properties/?format=json&page=36","previous":"http://glycodata.org/api/gdd/glyco-properties/?format=json&page=34","results":[{"id":681,"dataset":"heparin","entity":"enoxaparin","entity_group":"","entity_class":"LMWH","property":"disaccharide composition","property_key":"disaccharide_composition","value":"73.1","unit":"%","value_reported":"73.1","unit_reported":"%","method":"Experiment","method_detail":"mol% of TriS disaccharide (UA2S-GlcNS6S) in enoxaparin, LC-MS disaccharide analysis","conditions":"mol% of TriS disaccharide (UA2S-GlcNS6S) in enoxaparin, LC-MS disaccharide analysis","conditions_detail":"mol% of TriS disaccharide (UA2S-GlcNS6S) in enoxaparin, LC-MS disaccharide analysis | unit id: TriS (UA2S-GlcNS6S) | source: porcine-derived LMWH","doi":"10.1002/jps.23939","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3998821/","year":"2014","confidence":"high","comments":"\"Enoxaparin...TriS...73.1 ± 0.2\"  [Li Fu, Fuming Zhang, Guoyun Li, Akihiro Onishi, Ujjwal Bhaskar, Peilong Sun, Robert J. Linhardt, 2014, confidence: high]"},{"id":682,"dataset":"heparin","entity":"enoxaparin","entity_group":"","entity_class":"LMWH","property":"disaccharide composition","property_key":"disaccharide_composition","value":"15.2","unit":"%","value_reported":"15.2","unit_reported":"%","method":"Experiment","method_detail":"mol% of NS6S disaccharide (UA-GlcNS6S) in enoxaparin, LC-MS disaccharide analysis","conditions":"mol% of NS6S disaccharide (UA-GlcNS6S) in enoxaparin, LC-MS disaccharide analysis","conditions_detail":"mol% of NS6S disaccharide (UA-GlcNS6S) in enoxaparin, LC-MS disaccharide analysis | unit id: NS6S (UA-GlcNS6S) | source: porcine-derived LMWH","doi":"10.1002/jps.23939","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3998821/","year":"2014","confidence":"high","comments":"\"Enoxaparin...ΔDi-NS6S...15.2 ± 0.9\"  [Li Fu, Fuming Zhang, Guoyun Li, Akihiro Onishi, Ujjwal Bhaskar, Peilong Sun, Robert J. Linhardt, 2014, confidence: high]"},{"id":683,"dataset":"heparin","entity":"LMWH-II (enzymatic ultrafiltration)","entity_group":"","entity_class":"LMWH","property":"disaccharide composition","property_key":"disaccharide_composition","value":"76.8","unit":"%","value_reported":"76.8","unit_reported":"%","method":"Experiment","method_detail":"mol% of TriS disaccharide (UA2S-GlcNS6S) in a new LMWH (LMWH-II) made by enzymatic ultrafiltration, LC-MS disaccharide analysis","conditions":"mol% of TriS disaccharide (UA2S-GlcNS6S) in a new LMWH (LMWH-II) made by enzymatic ultrafiltration, LC-MS disaccharide analysis","conditions_detail":"mol% of TriS disaccharide (UA2S-GlcNS6S) in a new LMWH (LMWH-II) made by enzymatic ultrafiltration, LC-MS disaccharide analysis | unit id: TriS (UA2S-GlcNS6S) | source: porcine-derived LMWH","doi":"10.1002/jps.23939","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3998821/","year":"2014","confidence":"high","comments":"\"LMWH-II...TriS...76.8 ± 0.1\"  — TriS enriched relative to UFH  [Li Fu, Fuming Zhang, Guoyun Li, Akihiro Onishi, Ujjwal Bhaskar, Peilong Sun, Robert J. Linhardt, 2014, confidence: high]"},{"id":684,"dataset":"heparin","entity":"heparin (porcine intestinal)","entity_group":"","entity_class":"heparin (UFH)","property":"disaccharide composition","property_key":"disaccharide_composition","value":"68","unit":"%","value_reported":"68","unit_reported":"wt%","method":"Experiment","method_detail":"TriS content of porcine intestinal (PI) heparins reported as 67-69 wt/wt% (value entered as midpoint 68; range in quote/notes), LC-MS and HPLC-UV disaccharide analysis","conditions":"TriS content of porcine intestinal (PI) heparins reported as 67-69 wt/wt% (value entered as midpoint 68; range in quote/notes), LC-MS and HPLC-UV disaccharide analysis","conditions_detail":"TriS content of porcine intestinal (PI) heparins reported as 67-69 wt/wt% (value entered as midpoint 68; range in quote/notes), LC-MS and HPLC-UV disaccharide analysis | unit id: TriS (UA2S-GlcNS6S) | source: porcine intestinal | range wt pct: 67-69","doi":"10.1177/1076029616643822","source_url":"https://journals.sagepub.com/doi/full/10.1177/1076029616643822","year":"2016","confidence":"high","comments":"\"The TriS content of the PI heparins was very similar at 67 to 69 wt/wt%.\"  — Reported as a range 67-69 wt%; value field is the midpoint, exact range preserved in quote and conditions  [Kalib St Ange, Akihiro Onishi, Li Fu, Xiaojun Sun, Lei Lin, Daisuke Mori, Fuming Zhang, Jonathan S. Dordick, Jawed Fareed, Debra Hoppensteadt, Walter Jeske, Robert J. Linhardt, 2016, confidence: high]"},{"id":685,"dataset":"heparin","entity":"heparin (bovine lung)","entity_group":"","entity_class":"heparin (UFH)","property":"disaccharide composition","property_key":"disaccharide_composition","value":"78.5","unit":"%","value_reported":"78.5","unit_reported":"wt%","method":"Experiment","method_detail":"TriS content of bovine lung (BL) heparin reported as 70-87 wt/wt% (value entered as midpoint 78.5; range in quote/notes), LC-MS/HPLC-UV disaccharide analysis","conditions":"TriS content of bovine lung (BL) heparin reported as 70-87 wt/wt% (value entered as midpoint 78.5; range in quote/notes), LC-MS/HPLC-UV disaccharide analysis","conditions_detail":"TriS content of bovine lung (BL) heparin reported as 70-87 wt/wt% (value entered as midpoint 78.5; range in quote/notes), LC-MS/HPLC-UV disaccharide analysis | unit id: TriS (UA2S-GlcNS6S) | source: bovine lung | range wt pct: 70-87","doi":"10.1177/1076029616643822","source_url":"https://journals.sagepub.com/doi/full/10.1177/1076029616643822","year":"2016","confidence":"high","comments":"\"The TriS content of BL heparin was quite high ranging from 70 to 87 wt/wt.\"  — Range 70-87 wt%; value is midpoint, range preserved  [Kalib St Ange, Akihiro Onishi, Li Fu, Xiaojun Sun, Lei Lin, Daisuke Mori, Fuming Zhang, Jonathan S. Dordick, Jawed Fareed, Debra Hoppensteadt, Walter Jeske, Robert J. Linhardt, 2016, confidence: high]"},{"id":686,"dataset":"heparin","entity":"heparin (bovine intestinal)","entity_group":"","entity_class":"heparin (UFH)","property":"disaccharide composition","property_key":"disaccharide_composition","value":"53.5","unit":"%","value_reported":"53.5","unit_reported":"wt%","method":"Experiment","method_detail":"TriS content of bovine intestinal (BI) heparins reported as 51-56 wt/wt% (value entered as midpoint 53.5), LC-MS/HPLC-UV disaccharide analysis","conditions":"TriS content of bovine intestinal (BI) heparins reported as 51-56 wt/wt% (value entered as midpoint 53.5), LC-MS/HPLC-UV disaccharide analysis","conditions_detail":"TriS content of bovine intestinal (BI) heparins reported as 51-56 wt/wt% (value entered as midpoint 53.5), LC-MS/HPLC-UV disaccharide analysis | unit id: TriS (UA2S-GlcNS6S) | source: bovine intestinal | range wt pct: 51-56","doi":"10.1177/1076029616643822","source_url":"https://journals.sagepub.com/doi/full/10.1177/1076029616643822","year":"2016","confidence":"high","comments":"\"The TriS content of BI heparins was quite low at 51 to 56 wt/wt%.\"  — Bovine intestinal heparin has notably lower TriS than porcine intestinal or bovine lung  [Kalib St Ange, Akihiro Onishi, Li Fu, Xiaojun Sun, Lei Lin, Daisuke Mori, Fuming Zhang, Jonathan S. Dordick, Jawed Fareed, Debra Hoppensteadt, Walter Jeske, Robert J. Linhardt, 2016, confidence: high]"},{"id":687,"dataset":"heparin","entity":"heparin (bovine intestinal)","entity_group":"","entity_class":"heparin (UFH)","property":"disaccharide composition","property_key":"disaccharide_composition","value":"23.5","unit":"%","value_reported":"23.5","unit_reported":"wt%","method":"Experiment","method_detail":"NS2S content of bovine intestinal (BI) heparins reported as 15-32 wt/wt% (value entered as midpoint 23.5), LC-MS/HPLC-UV disaccharide analysis","conditions":"NS2S content of bovine intestinal (BI) heparins reported as 15-32 wt/wt% (value entered as midpoint 23.5), LC-MS/HPLC-UV disaccharide analysis","conditions_detail":"NS2S content of bovine intestinal (BI) heparins reported as 15-32 wt/wt% (value entered as midpoint 23.5), LC-MS/HPLC-UV disaccharide analysis | unit id: NS2S (UA2S-GlcNS) | source: bovine intestinal | range wt pct: 15-32","doi":"10.1177/1076029616643822","source_url":"https://journals.sagepub.com/doi/full/10.1177/1076029616643822","year":"2016","confidence":"high","comments":"\"BI heparins showed considerable amount of NS2S content, 15 to 32 wt/wt%.\"  — BI heparin enriched in NS2S relative to porcine; range 15-32 wt%, value is midpoint  [Kalib St Ange, Akihiro Onishi, Li Fu, Xiaojun Sun, Lei Lin, Daisuke Mori, Fuming Zhang, Jonathan S. Dordick, Jawed Fareed, Debra Hoppensteadt, Walter Jeske, Robert J. Linhardt, 2016, confidence: high]"},{"id":688,"dataset":"heparin","entity":"heparin (beef/bovine lung)","entity_group":"","entity_class":"heparin (UFH)","property":"disaccharide composition","property_key":"disaccharide_composition","value":"85","unit":"%","value_reported":"85","unit_reported":"%","method":"Review","method_detail":"Fraction of the trisulfated disaccharide IdoA(2S)-GlcNS(6S) in beef lung heparin (review statement)","conditions":"Fraction of the trisulfated disaccharide IdoA(2S)-GlcNS(6S) in beef lung heparin (review statement)","conditions_detail":"Fraction of the trisulfated disaccharide IdoA(2S)-GlcNS(6S) in beef lung heparin (review statement) | unit id: TriS / IdoA(2S)-GlcNS(6S) | source: beef lung","doi":"","source_url":"https://en.wikipedia.org/wiki/Heparan_sulfate","year":"2024","confidence":"medium","comments":"\"IdoA(2S)-GlcNS(6S) makes up 85% of heparins from beef lung\"  — Tertiary/review source; classic textbook contrast value  [Wikipedia contributors, 2024, confidence: medium]"},{"id":689,"dataset":"heparin","entity":"heparin (porcine intestinal mucosa)","entity_group":"","entity_class":"heparin (UFH)","property":"disaccharide composition","property_key":"disaccharide_composition","value":"75","unit":"%","value_reported":"75","unit_reported":"%","method":"Review","method_detail":"Fraction of the trisulfated disaccharide IdoA(2S)-GlcNS(6S) in porcine intestinal mucosa heparin (review statement)","conditions":"Fraction of the trisulfated disaccharide IdoA(2S)-GlcNS(6S) in porcine intestinal mucosa heparin (review statement)","conditions_detail":"Fraction of the trisulfated disaccharide IdoA(2S)-GlcNS(6S) in porcine intestinal mucosa heparin (review statement) | unit id: TriS / IdoA(2S)-GlcNS(6S) | source: porcine intestinal mucosa","doi":"","source_url":"https://en.wikipedia.org/wiki/Heparan_sulfate","year":"2024","confidence":"medium","comments":"\"about 75% of those from porcine intestinal mucosa\"  — Tertiary/review source; classic ~75% porcine vs 85% beef-lung contrast  [Wikipedia contributors, 2024, confidence: medium]"},{"id":690,"dataset":"heparin","entity":"heparan sulfate (general)","entity_group":"","entity_class":"heparan sulfate","property":"disaccharide composition","property_key":"disaccharide_composition","value":"50","unit":"%","value_reported":"50","unit_reported":"%","method":"Review","method_detail":"The most common HS disaccharide GlcA-GlcNAc (N-acetylated, unsulfated) typically makes up ~50% of total (review statement) - contrast with the trisulfated-dominant heparin","conditions":"The most common HS disaccharide GlcA-GlcNAc (N-acetylated, unsulfated) typically makes up ~50% of total (review statement) - contrast with the trisulfated-dominant heparin","conditions_detail":"The most common HS disaccharide GlcA-GlcNAc (N-acetylated, unsulfated) typically makes up ~50% of total (review statement) - contrast with the trisulfated-dominant heparin | unit id: NA / unsulfated (GlcA-GlcNAc) | source: general heparan sulfate","doi":"","source_url":"https://en.wikipedia.org/wiki/Heparan_sulfate","year":"2024","confidence":"medium","comments":"\"The most common disaccharide unit within heparan sulfate is composed of a glucuronic acid (GlcA) linked to N-acetylglucosamine (GlcNAc), typically making up around 50% of the total\"  — Key contrast: HS is dominated by unsulfated N-acetylated disaccharide (~50%), opposite of heparin (trisulfated-dominant)  [Wikipedia contributors, 2024, confidence: medium]"},{"id":691,"dataset":"heparin","entity":"heparan sulfate (human serum, platelet-poor)","entity_group":"","entity_class":"heparan sulfate","property":"disaccharide composition","property_key":"disaccharide_composition","value":"37.2","unit":"%","value_reported":"37.2","unit_reported":"%","method":"Experiment","method_detail":"mol% of IV-A (UA-GlcNAc, unsulfated/N-acetylated) in HS/heparin-derived disaccharides from commercial platelet-poor human serum, LC-MS","conditions":"mol% of IV-A (UA-GlcNAc, unsulfated/N-acetylated) in HS/heparin-derived disaccharides from commercial platelet-poor human serum, LC-MS","conditions_detail":"mol% of IV-A (UA-GlcNAc, unsulfated/N-acetylated) in HS/heparin-derived disaccharides from commercial platelet-poor human serum, LC-MS | unit id: 0S / NA (UA-GlcNAc), IV-A | source: human serum (platelet poor)","doi":"10.1021/ac2001077","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3094484/","year":"2011","confidence":"high","comments":"\"37.2 ± 0.2\"  — Unsulfated disaccharide is the most abundant - characteristic of HS, not heparin  [Wei Wei, Milady R. Niñonuevo, Anish Sharma, Lieza M. Danan-Leon, Julie A. Leary, 2011, confidence: high]"},{"id":692,"dataset":"heparin","entity":"heparan sulfate (human serum, platelet-poor)","entity_group":"","entity_class":"heparan sulfate","property":"disaccharide composition","property_key":"disaccharide_composition","value":"14.6","unit":"%","value_reported":"14.6","unit_reported":"%","method":"Experiment","method_detail":"mol% of IV-S (UA-GlcNS, NS) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS","conditions":"mol% of IV-S (UA-GlcNS, NS) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS","conditions_detail":"mol% of IV-S (UA-GlcNS, NS) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS | unit id: NS (UA-GlcNS), IV-S | source: human serum (platelet poor)","doi":"10.1021/ac2001077","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3094484/","year":"2011","confidence":"high","comments":"\"14.6 ± 2.0\"  [Wei Wei, Milady R. Niñonuevo, Anish Sharma, Lieza M. Danan-Leon, Julie A. Leary, 2011, confidence: high]"},{"id":693,"dataset":"heparin","entity":"heparan sulfate (human serum, platelet-poor)","entity_group":"","entity_class":"heparan sulfate","property":"disaccharide composition","property_key":"disaccharide_composition","value":"14.3","unit":"%","value_reported":"14.3","unit_reported":"%","method":"Experiment","method_detail":"mol% of II-A (UA-GlcNAc6S, 6S) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS","conditions":"mol% of II-A (UA-GlcNAc6S, 6S) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS","conditions_detail":"mol% of II-A (UA-GlcNAc6S, 6S) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS | unit id: 6S (UA-GlcNAc6S), II-A | source: human serum (platelet poor)","doi":"10.1021/ac2001077","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3094484/","year":"2011","confidence":"high","comments":"\"14.3 ± 1.0\"  [Wei Wei, Milady R. Niñonuevo, Anish Sharma, Lieza M. Danan-Leon, Julie A. Leary, 2011, confidence: high]"},{"id":694,"dataset":"heparin","entity":"heparan sulfate (human serum, platelet-poor)","entity_group":"","entity_class":"heparan sulfate","property":"disaccharide composition","property_key":"disaccharide_composition","value":"5.9","unit":"%","value_reported":"5.9","unit_reported":"%","method":"Experiment","method_detail":"mol% of I-S (UA2S-GlcNS6S, TriS) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS","conditions":"mol% of I-S (UA2S-GlcNS6S, TriS) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS","conditions_detail":"mol% of I-S (UA2S-GlcNS6S, TriS) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS | unit id: TriS (UA2S-GlcNS6S), I-S | source: human serum (platelet poor)","doi":"10.1021/ac2001077","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3094484/","year":"2011","confidence":"high","comments":"\"5.9 ± 0.6\"  — TriS is only ~6% in serum HS, vs ~65-85% in heparin - the central composition contrast  [Wei Wei, Milady R. Niñonuevo, Anish Sharma, Lieza M. Danan-Leon, Julie A. Leary, 2011, confidence: high]"},{"id":695,"dataset":"heparin","entity":"heparan sulfate (human serum, platelet-poor)","entity_group":"","entity_class":"heparan sulfate","property":"disaccharide composition","property_key":"disaccharide_composition","value":"12.1","unit":"%","value_reported":"12.1","unit_reported":"%","method":"Experiment","method_detail":"mol% of II-S (UA-GlcNS6S, NS6S) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS","conditions":"mol% of II-S (UA-GlcNS6S, NS6S) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS","conditions_detail":"mol% of II-S (UA-GlcNS6S, NS6S) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS | unit id: NS6S (UA-GlcNS6S), II-S | source: human serum (platelet poor)","doi":"10.1021/ac2001077","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3094484/","year":"2011","confidence":"high","comments":"\"12.1 ± 2.1\"  [Wei Wei, Milady R. Niñonuevo, Anish Sharma, Lieza M. Danan-Leon, Julie A. Leary, 2011, confidence: high]"},{"id":696,"dataset":"heparin","entity":"heparan sulfate (human serum, male AB)","entity_group":"","entity_class":"heparan sulfate","property":"disaccharide composition","property_key":"disaccharide_composition","value":"52.9","unit":"%","value_reported":"52.9","unit_reported":"%","method":"Experiment","method_detail":"mol% of IV-A (UA-GlcNAc, unsulfated/N-acetylated) in HS/heparin-derived disaccharides from commercial male AB human serum, LC-MS","conditions":"mol% of IV-A (UA-GlcNAc, unsulfated/N-acetylated) in HS/heparin-derived disaccharides from commercial male AB human serum, LC-MS","conditions_detail":"mol% of IV-A (UA-GlcNAc, unsulfated/N-acetylated) in HS/heparin-derived disaccharides from commercial male AB human serum, LC-MS | unit id: 0S / NA (UA-GlcNAc), IV-A | source: human serum (male AB)","doi":"10.1021/ac2001077","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3094484/","year":"2011","confidence":"high","comments":"\"52.9 ± 1.7\"  — Unsulfated N-acetylated dominant in serum HS  [Wei Wei, Milady R. Niñonuevo, Anish Sharma, Lieza M. Danan-Leon, Julie A. Leary, 2011, confidence: high]"},{"id":697,"dataset":"heparin","entity":"heparan sulfate (human serum, male AB)","entity_group":"","entity_class":"heparan sulfate","property":"disaccharide composition","property_key":"disaccharide_composition","value":"0.5","unit":"%","value_reported":"0.5","unit_reported":"%","method":"Experiment","method_detail":"mol% of I-S (UA2S-GlcNS6S, TriS) in HS/heparin-derived disaccharides from male AB human serum, LC-MS","conditions":"mol% of I-S (UA2S-GlcNS6S, TriS) in HS/heparin-derived disaccharides from male AB human serum, LC-MS","conditions_detail":"mol% of I-S (UA2S-GlcNS6S, TriS) in HS/heparin-derived disaccharides from male AB human serum, LC-MS | unit id: TriS (UA2S-GlcNS6S), I-S | source: human serum (male AB)","doi":"10.1021/ac2001077","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3094484/","year":"2011","confidence":"high","comments":"\"0.5 ± 0.2\"  — TriS essentially absent in this serum HS sample  [Wei Wei, Milady R. Niñonuevo, Anish Sharma, Lieza M. Danan-Leon, Julie A. Leary, 2011, confidence: high]"},{"id":698,"dataset":"heparin","entity":"heparan sulfate (human serum, male AB)","entity_group":"","entity_class":"heparan sulfate","property":"disaccharide composition","property_key":"disaccharide_composition","value":"10.5","unit":"%","value_reported":"10.5","unit_reported":"%","method":"Experiment","method_detail":"mol% of III-S (UA2S-GlcNS, NS2S) in HS/heparin-derived disaccharides from male AB human serum, LC-MS","conditions":"mol% of III-S (UA2S-GlcNS, NS2S) in HS/heparin-derived disaccharides from male AB human serum, LC-MS","conditions_detail":"mol% of III-S (UA2S-GlcNS, NS2S) in HS/heparin-derived disaccharides from male AB human serum, LC-MS | unit id: NS2S (UA2S-GlcNS), III-S | source: human serum (male AB)","doi":"10.1021/ac2001077","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3094484/","year":"2011","confidence":"high","comments":"\"10.5 ± 2.1\"  [Wei Wei, Milady R. Niñonuevo, Anish Sharma, Lieza M. Danan-Leon, Julie A. Leary, 2011, confidence: high]"},{"id":699,"dataset":"heparin","entity":"heparan sulfate (human lung, donor m70)","entity_group":"","entity_class":"heparan sulfate","property":"disaccharide composition","property_key":"disaccharide_composition","value":"70.7","unit":"%","value_reported":"70.7","unit_reported":"%","method":"Experiment","method_detail":"Upper bound of TriS (UA2S-GlcNS6S) mol% across HS fractions from a 70-year-old male human lung; reported range 59.7-70.7%. Value is the stated upper bound; range in conditions/notes","conditions":"Upper bound of TriS (UA2S-GlcNS6S) mol% across HS fractions from a 70-year-old male human lung; reported range 59.7-70.7%. Value is the stated upper bound; range in conditions/notes","conditions_detail":"Upper bound of TriS (UA2S-GlcNS6S) mol% across HS fractions from a 70-year-old male human lung; reported range 59.7-70.7%. Value is the stated upper bound; range in conditions/notes | unit id: TriS (UA2S-GlcNS6S) | source: human lung (male, 70 y) | range pct: 59.7-70.7","doi":"10.3390/molecules26185512","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8469465/","year":"2021","confidence":"medium","comments":"\"UA2S-GlcNS6S: 59.7-70.7%\"  — Unusually highly-sulfated lung HS approaching heparin-like TriS levels; reported as a range across fractions, value = upper bound  [Derler, Kitic, Gerlza, Kungl, 2021, confidence: medium]"},{"id":700,"dataset":"heparin","entity":"heparan sulfate (human lung, donor f92)","entity_group":"","entity_class":"heparan sulfate","property":"disaccharide composition","property_key":"disaccharide_composition","value":"44.3","unit":"%","value_reported":"44.3","unit_reported":"%","method":"Experiment","method_detail":"Upper bound of unsulfated UA-GlcNAc (NA/0S) mol% across HS fractions from a 92-year-old female human lung; reported range 27.7-44.3%. Value = stated upper bound; range in conditions/notes","conditions":"Upper bound of unsulfated UA-GlcNAc (NA/0S) mol% across HS fractions from a 92-year-old female human lung; reported range 27.7-44.3%. Value = stated upper bound; range in conditions/notes","conditions_detail":"Upper bound of unsulfated UA-GlcNAc (NA/0S) mol% across HS fractions from a 92-year-old female human lung; reported range 27.7-44.3%. Value = stated upper bound; range in conditions/notes | unit id: 0S / NA (UA-GlcNAc) | source: human lung (female, 92 y) | range pct: 27.7-44.3","doi":"10.3390/molecules26185512","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8469465/","year":"2021","confidence":"medium","comments":"\"UA-GlcNAc: 27.7-44.3%\"  — More typical low-sulfation HS phenotype; high unsulfated content. Donor-to-donor HS heterogeneity is large  [Derler, Kitic, Gerlza, Kungl, 2021, confidence: medium]"}]}